Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of docetaxel versus docetaxel + radium-223 for metastatic castration-resistant prostate cancer
MOH_2023-07-11_012807Phase 3Not yet recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing Docetaxel + prednisone with Docetaxel + prednisone + radium-223 (2 arms). Planned start Jul 2023; status: not yet recruiting.
02
Drugs
docetaxelradium-223 dichlorideprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2023-07-11_012807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-11_012807.